A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...

President Donald Trump's communications pause for HHS, FDA and other health-related agencies could push some drug approval ...

Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential ...

Merck's Keytruda and Eisai's Lenvima combo with chemo failed survival endpoint in gastroesophageal cancer study, but ...

Aardvark Therapeutics files for IPO. Company develops hunger-targeting obesity drug ARD-101 and ARD-201, led by CEO Tien Lee.

Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...

Moderna’s chief information officer Brad Miller is 'retiring' in February, a company spokesperson confirmed to Endpoints News ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...

ALX Oncology is forging ahead with a treatment approach that has long been abandoned by other drugmakers, eyeing a potential ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical ...